Hyperkalaemia among hospital admissions: prevalence, risk factors, treatment and impact on length of stay
- PMID: 39696056
- PMCID: PMC11654175
- DOI: 10.1186/s12882-024-03863-w
Hyperkalaemia among hospital admissions: prevalence, risk factors, treatment and impact on length of stay
Abstract
Background: Hyperkalaemia is one of the common electrolyte disorders among hospital patients, affected by many risk factors including medications and medical conditions. Prompt treatment is important given its impact on patient mortality and morbidity, which can lead to negative patient outcomes and healthcare resource utilisation. This study aims to describe the prevalence, characteristics, and treatment of patients admitted to hospitals with hyperkalaemia and compare findings between patients with kidney failure on maintenance haemodialysis therapy and patients without kidney failure. It also aims to identify associations between hyperkalaemia and hospital length of stay.
Methods: We undertook a retrospective cohort study on adult patients admitted to Townsville University Hospital between 1st January 2018 and 31st December 2022 (n = 99,047). Patients were included if they had a serum potassium result of 5.1 mmol/L and above during their admission/s. Statistical analysis was conducted using several methods. A Welch's t test and Chi-square test were employed to assess differences between groups of patients with kidney failure on maintenance haemodialysis therapy and those without kidney failure. For comparison among multiple groups with varying severities of hyperkalaemia, the Kruskal-Wallis test with Mann-Whitney U test and logistic regression were used.
Results: 8,775 hyperkalaemic patients were included in the study, with a mean age of 64.7 years. The prevalence of hyperkalaemia was 8.9% of patients. Risk factors for hyperkalaemia were highly prevalent among those who had the condition during their admissions. Patients with kidney failure on haemodialysis who had hyperkalaemia were, on average, 6 years younger, more often Indigenous, and experienced more severe hyperkalaemia compared to other patients without kidney failure. There was a notable difference in hyperkalaemia treatment between groups with varying degrees of hyperkalaemia severity. Hyperkalaemia was not found to be associated with prolonged hospital stay.
Conclusion: Hyperkalaemia is common among hospital admissions. Patients with kidney failure on haemodialysis are at higher risk of developing severe hyperkalaemia. Treatment for hyperkalaemia was variable and likely insufficient. Timely detection and treatment of hyperkalaemia is recommended.
Keywords: Haemodialysis; Hospital length of stay; Hyperkalaemia; Risk factors; Treatment.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This project was approved by Townsville University Hospital’s Audit, Quality and Innovation Review (AQUIRE) panel (approval number THHSAQUIRE1573) which incorporates Townsville Hospital and Health Service Human Research and Ethics Committee exemption review and approval. This included approval for waiver of consent as per the Townsville Hospital and Health Service Human Research and Ethics Committee and the relevant legislation (Queensland Hospital and Health Boards Act (Sect. 150; 2011)). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K).BMC Nephrol. 2023 Aug 9;24(1):233. doi: 10.1186/s12882-023-03261-8. BMC Nephrol. 2023. PMID: 37559023 Free PMC article.
-
Can we predict who will develop postoperative hyperkalaemia after parathyroidectomy in dialysis patients with secondary hyperparathyroidism?BMC Nephrol. 2019 Jun 20;20(1):225. doi: 10.1186/s12882-019-1416-9. BMC Nephrol. 2019. PMID: 31221111 Free PMC article.
-
Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.Eur J Clin Invest. 2021 Aug;51(8):e13551. doi: 10.1111/eci.13551. Epub 2021 Mar 31. Eur J Clin Invest. 2021. PMID: 33786826 Free PMC article.
-
Management of hyperkalaemia in chronic kidney disease.Nat Rev Nephrol. 2014 Nov;10(11):653-62. doi: 10.1038/nrneph.2014.168. Epub 2014 Sep 16. Nat Rev Nephrol. 2014. PMID: 25223988 Review.
-
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2. Cochrane Database Syst Rev. 2020. PMID: 32588430 Free PMC article.
Cited by
-
Hyperkalemia Caused by Potassium-Enriched Salt in a Hospitalized Patient.Cureus. 2025 Jun 24;17(6):e86704. doi: 10.7759/cureus.86704. eCollection 2025 Jun. Cureus. 2025. PMID: 40718189 Free PMC article.
References
-
- Mehta A, Emmett M. The importance of a just right serum potassium level. Am J Nephrol. 2017;46(3):210–2. 10.1159/000479803 - PubMed
-
- Hougen I, Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalisations, and Intensive Care Unit admissions in a population-based retrospective cohort. Kidney Int Rep. 2021;6(5):1309–16. 10.1016/j.ekir.2021.02.038 - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical